Turkey-based science-focused company expands U.S. availability with research-driven botanical formulations coming soon to Amazon. The post Carmed PharmaceuticalsTurkey-based science-focused company expands U.S. availability with research-driven botanical formulations coming soon to Amazon. The post Carmed Pharmaceuticals

Carmed Pharmaceuticals to Launch Standardized Carvacrol Formulations on Amazon

2026/03/24 18:00
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
Boca Raton, Florida (Newsworthy.ai) Tuesday Mar 24, 2026 @ 4:00 AM Mountain —

Carmed Pharmaceuticals, a science-driven company specializing in standardized carvacrol-based formulations, announced plans to expand its U.S. presence with an upcoming launch on Amazon.

The expansion builds on Carmed’s entry into the United States market and represents the next step in making its research-driven botanical formulations more accessible to U.S. consumers through one of the world’s largest online retail platforms.

Carmed’s approach integrates traditional botanical knowledge with modern pharmaceutical methodology to develop standardized formulations designed to support immune resilience, cellular health, and overall physiological balance.

Expanding Access Through Amazon

The planned Amazon launch is designed to provide broader access to Carmed’s formulations while supporting the company’s long-term strategy of combining scientific development with scalable distribution.

By leveraging Amazon’s platform, Carmed aims to reach a wider audience seeking standardized, quality-controlled botanical formulations grounded in research and formulation science.

“Amazon allows us to make our formulations more accessible while maintaining our focus on scientific integrity and standardization,” said Mustafa Can, Founder of Carmed Pharmaceuticals. “Our goal is to ensure that every product reflects the same level of research, consistency, and quality that defines our development process.”

The company’s U.S. rollout is focused on accessibility, consistency, and maintaining alignment with regulatory standards as it expands into new distribution channels.

Product Portfolio Coming to Amazon

As part of its Amazon launch, Carmed Pharmaceuticals plans to introduce several of its flagship formulations:

  • Vacrol® Kids Spray – A carvacrol-based spray formulated to support upper respiratory wellness and microbial balance for children ages 4-11.

  • S-Mix® – A synergy-driven formulation designed to support immune function and healthy cellular activity.

  • Vacrol® Capsule – A standardized carvacrol formulation developed to support microbial balance and immune resilience.

  • Vacrol-M® Capsule – A multi-component botanical formulation designed to support immune function and respiratory wellness.

  • Omevaq-3® – A targeted formulation developed to support cellular energy metabolism and cognitive wellness.

Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified.

According to the company, Carmed’s formulations are developed using standardized processes designed to ensure consistency, reproducibility, and quality control across product batches.

Scientific Foundation and Ongoing Research

Carmed’s development model is supported by ongoing research and collaboration with academic institutions, laboratories, and medical researchers focused on formulation science and bioactive compound evaluation.

In January 2026, a study published in the peer-reviewed journal Plants examined Vacrol® and S-Mix® in preclinical laboratory and in ovo models as part of broader scientific investigation into carvacrol-based formulations and multicomponent botanical interactions.

The company emphasizes that such research reflects scientific investigation into botanical bioactivity and formulation design and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.

U.S. Market Expansion

Carmed states that its U.S. strategy is centered on building long-term credibility through scientific rigor, regulatory alignment, and consistent product quality as it expands distribution.

“The Amazon launch is an important step in making Carmed’s formulations available to a broader audience in the United States,” said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. “We are focused on delivering consistent, high-quality products while continuing to build awareness around our research-driven approach to formulation development.”

The Amazon launch represents a key milestone in that strategy, enabling broader consumer access while supporting continued investment in research and formulation development.

Availability timelines and product listings on Amazon will be announced in the coming weeks.

About Carmed Pharmaceuticals

Carmed Pharmaceuticals is a research-driven company specializing in standardized, mechanism-based botanical formulations rooted in Anatolia’s rich botanical heritage. Integrating traditional plant knowledge with modern pharmaceutical technology, Carmed focuses on analytical validation, quality control, and reproducible formulation design.

Officially established in 2019 following years of focused research and development, the company operates with nearly 15 years of industry experience. All products are manufactured in accordance with Good Manufacturing Practice (GMP) principles and relevant regulatory standards, emphasizing safe production, environmental awareness, and continuous quality improvement.

Carmed develops standardized formulations designed to support preventive wellness, immune resilience, and cellular health through science-informed, quality-controlled processes.

Visit Carmed Pharmaceuticals website and visit them on Instagram.


This press release is distributed by the Newsworthy.ai™ Press Release Newswire – News Marketing Platform™. The reference URL for this press release is located here Carmed Pharmaceuticals to Launch Standardized Carvacrol Formulations on Amazon.

The post Carmed Pharmaceuticals to Launch Standardized Carvacrol Formulations on Amazon appeared first on citybuzz.

Market Opportunity
Union Logo
Union Price(U)
$0.0009896
$0.0009896$0.0009896
-17.31%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

BNB's market capitalization surpassed BYD, Pfizer, and other companies, rising to 155th in the world.

BNB's market capitalization surpassed BYD, Pfizer, and other companies, rising to 155th in the world.

PANews reported on September 18 that according to 8marketcap data, BNB's market value exceeded that of companies such as BYD and Pfizer, ranking 155th in the global asset market value.
Share
PANews2025/09/18 16:38
CME Group to Launch Solana and XRP Futures Options

CME Group to Launch Solana and XRP Futures Options

The post CME Group to Launch Solana and XRP Futures Options appeared on BitcoinEthereumNews.com. An announcement was made by CME Group, the largest derivatives exchanger worldwide, revealed that it would introduce options for Solana and XRP futures. It is the latest addition to CME crypto derivatives as institutions and retail investors increase their demand for Solana and XRP. CME Expands Crypto Offerings With Solana and XRP Options Launch According to a press release, the launch is scheduled for October 13, 2025, pending regulatory approval. The new products will allow traders to access options on Solana, Micro Solana, XRP, and Micro XRP futures. Expiries will be offered on business days on a monthly, and quarterly basis to provide more flexibility to market players. CME Group said the contracts are designed to meet demand from institutions, hedge funds, and active retail traders. According to Giovanni Vicioso, the launch reflects high liquidity in Solana and XRP futures. Vicioso is the Global Head of Cryptocurrency Products for the CME Group. He noted that the new contracts will provide additional tools for risk management and exposure strategies. Recently, CME XRP futures registered record open interest amid ETF approval optimism, reinforcing confidence in contract demand. Cumberland, one of the leading liquidity providers, welcomed the development and said it highlights the shift beyond Bitcoin and Ethereum. FalconX, another trading firm, added that rising digital asset treasuries are increasing the need for hedging tools on alternative tokens like Solana and XRP. High Record Trading Volumes Demand Solana and XRP Futures Solana futures and XRP continue to gain popularity since their launch earlier this year. According to CME official records, many have bought and sold more than 540,000 Solana futures contracts since March. A value that amounts to over $22 billion dollars. Solana contracts hit a record 9,000 contracts in August, worth $437 million. Open interest also set a record at 12,500 contracts.…
Share
BitcoinEthereumNews2025/09/18 01:39
Time Management For Entrepreneurs

Time Management For Entrepreneurs

When you’re managing everything on your own, time is your biggest asset. Yet while most entrepreneurs focus on leadership, growth and networking, they often overlook
Share
Techbullion2026/03/24 20:21